Compounded Wegovy: What It Is, Whether It's Legal, and the Best Alternatives in March–April 2026

Wegovy vs. Compounded Semaglutide: What's the Same, What's Different

Wegovy, manufactured by Novo Nordisk, is a subcutaneous injection of semaglutide at doses escalating to 2.4mg/week. It is FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition. It received a landmark additional FDA approval in March 2024 for reducing cardiovascular events in the same population.

What's the same between Wegovy and compounded semaglutide:

• The active pharmaceutical ingredient: semaglutide
• The mechanism of action: GLP-1 receptor agonism
• The route of administration: subcutaneous injection
• The clinical effects when used at equivalent doses: weight loss, appetite suppression, metabolic improvement

What's different:

• FDA approval: Wegovy is FDA-approved; compounded semaglutide is not. The compounded version has not undergone Novo Nordisk's manufacturing quality program or the drug approval process.
• Delivery device: Wegovy comes in a pre-loaded, pre-calibrated auto-injector pen. Compounded semaglutide typically comes in a multi-dose vial that you draw from with a syringe.
• Price: Wegovy lists at approximately $1,300–$1,400/month. Compounded semaglutide at equivalent doses costs $200–$350/month.
• Availability: Brand-name Wegovy requires insurance coverage or out-of-pocket payment at full list price. Compounded semaglutide is available directly through telehealth programs.
• Quality oversight: Novo Nordisk's manufacturing is subject to FDA inspection and their proprietary quality controls. Compounding pharmacies are subject to state board oversight and, for 503B facilities, FDA inspection — but not the same level as a branded drug manufacturer.

Is Compounded Semaglutide Legal in March 2026?

This is the question everyone searches for and deserves a direct answer. The short version: legally complex, actively contested, but substantial legitimate programs continue operating.

Here's the timeline: when semaglutide was on the FDA's drug shortage list (2022–2024), compounding under the shortage exemption was clearly permitted under Section 503A and 503B of the FD&C Act. In early 2025, the FDA declared the shortage resolved. The Outsourcing Facilities Association (OFA) challenged this in federal court, arguing the shortage determination was flawed. Judge Matthew Pittman of the Northern District of Texas ruled in favor of the FDA in the initial proceeding, but the litigation is ongoing as of March 2026.

In practical terms: many 503A pharmacies continue to compound semaglutide under patient-specific prescriptions, arguing the individual compounding authority under 503A is distinct from the shortage-based authority. Some 503B outsourcing facilities have paused semaglutide compounding; others continue, citing ongoing litigation. The situation is in flux.

If regulatory certainty is important to you, compounded tirzepatide is the more straightforward option right now — it remains on the FDA shortage list as of March 2026 and its compounding is not currently under legal challenge. See our full legal status guide for the complete picture.

Should You Try to Get Brand-Name Wegovy Instead?

Brand-name Wegovy makes sense in several scenarios:

• You have insurance that covers it. Commercial insurance increasingly covers Wegovy for obesity — prior authorization is usually required but many plans do cover it. If your plan covers Wegovy and your co-pay is reasonable ($0–$100/month), the brand-name product with its FDA-approved manufacturing, convenient pen device, and established supply chain is a reasonable choice.
• You qualify for Novo Nordisk's savings program. Patients with commercial insurance may pay as little as $0–$25/month through the Wegovy savings card. Novo Nordisk also has patient assistance programs for qualifying uninsured patients.
• You prefer the pen device. The Wegovy auto-injector pen is genuinely more convenient than drawing from a vial. If injection anxiety is a significant concern, the pre-loaded pen may be worth the price difference to you.

Compounded semaglutide makes more sense when: you have no insurance coverage and can't afford $1,300/month, you don't qualify for Novo Nordisk's savings programs, you want faster access (telehealth programs typically ship within days; brand-name Wegovy may require prior authorization turnaround time), or you want tirzepatide specifically and can't afford brand-name Zepbound.

Compounded Semaglutide at the 2.4mg Dose: Can You Get It?

Wegovy's maintenance dose is 2.4mg/week of semaglutide. Many patients ask whether compounded programs offer this high a dose. The answer: yes, many do — but you typically don't start there. Standard titration begins at 0.25mg and escalates over 4–5 months to reach therapeutic doses. Some patients achieve their goals at 1–2mg; others need the full 2.4mg.

Compounding pharmacies can prepare semaglutide at any dose prescribed by your physician. The concentration in your vial will be adjusted so you're drawing a convenient volume at each dose. Most programs start you at the lower end and work up based on your tolerance and results.